Role of C-reactive protein in urological cancers: A useful biomarker for predicting outcomes

International Journal of Urology

Volumn 20, Issue 2, 2013, Pages 161-171

  Saito, Kazutaka ^a   Kihara, Kazunori ^a  

^a TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

Author keywords

Biomarker; C reactive protein; Prognosis; Urological cancer

Indexed keywords

C REACTIVE PROTEIN;

CANCER GROWTH; CANCER PATIENT; CANCER PROGNOSIS; HUMAN; KIDNEY CARCINOMA; PREDICTION; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; TESTIS CANCER; TRANSITIONAL CELL CARCINOMA;

AGED; AGED, 80 AND OVER; C-REACTIVE PROTEIN; CARCINOMA, RENAL CELL; CARCINOMA, TRANSITIONAL CELL; DISEASE-FREE SURVIVAL; EVIDENCE-BASED MEDICINE; FEMALE; HUMANS; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PREVALENCE; PROGNOSIS; PROSTATIC NEOPLASMS; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL; URINARY BLADDER NEOPLASMS; UROLOGIC NEOPLASMS;

EID: 84873258696     PISSN: 09198172     EISSN: 14422042     Source Type: Journal    
DOI: 10.1111/j.1442-2042.2012.03121.x     Document Type: Review

References (88)

1. Conference NIH-FDA. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin. Pharmacol. Ther. 2001; 69: 89-95.
2. Ferrero-Miliani L, Nielsen OH, Andersen PS, Girardin SE. Chronic inflammation: importance of NOD2 and NALP3 in interleukin-1beta generation. Clin. Exp. Immunol. 2007; 147: 227-35.
3. Grivennikov SI, Greten FR, Karin M. Immunity, inflammation, and cancer. Cell 2010; 140: 883-99.
4. Mantovani A, Allavena P, Sica A, Balkwill F. Cancer-related inflammation. Nature 2008; 454: 436-44.
5. Okamoto M, Lee C, Oyasu R. Interleukin-6 as a paracrine and autocrine growth factor in human prostatic carcinoma cells in vitro. Cancer Res. 1997; 57: 141-6.
6. Okamoto M, Hattori K, Oyasu R. Interleukin-6 functions as an autocrine growth factor in human bladder carcinoma cell lines in vitro. Int. J. Cancer 1997; 72: 149-54.
7. Miki S, Iwano M, Miki Y et al. Interleukin-6 (IL-6) functions as an in vitro autocrine growth factor in renal cell carcinomas. FEBS Lett. 1989; 250: 607-10.
8. Koo AS, Armstrong C, Bochner B et al. Interleukin-6 and renal cell cancer: production, regulation, and growth effects. Cancer Immunol. Immunother. 1992; 35: 97-105.
9. Roxburgh CS, McMillan DC. Role of systemic inflammatory response in predicting survival in patients with primary operable cancer. Future Oncol. 2010; 6: 149-63.
10. Dewys WD, Begg C, Lavin PT et al. Prognostic effect of weight loss prior to chemotherapy in cancer patients. Eastern Cooperative Oncology Group. Am. J. Med. 1980; 69: 491-7.
11. Graf W, Bergstrom R, Pahlman L, Glimelius B. Appraisal of a model for prediction of prognosis in advanced colorectal cancer. Eur. J. Cancer 1994; 30A: 453-7.
12. Maltoni M, Caraceni A, Brunelli C et al. Prognostic factors in advanced cancer patients: evidence-based clinical recommendations - a study by the Steering Committee of the European Association for Palliative Care. J. Clin. Oncol. 2005; 23: 6240-8.
13. McMillan DC. An inflammation-based prognostic score and its role in the nutrition-based management of patients with cancer. Proc. Nutr. Soc. 2008; 67: 257-62.
14. Shinohara N, Kumagai A, Kanagawa K et al. Multicenter phase II trial of combination therapy with meloxicam, a cox-2 inhibitor, and natural interferon-alpha for metastatic renal cell carcinoma. Jpn. J. Clin. Oncol. 2009; 39: 720-6.
15. Tatokoro M, Fujii Y, Kawakami S et al. Phase-II trial of combination treatment of interferon-alpha, cimetidine, cyclooxygenase-2 inhibitor and renin-angiotensin-system inhibitor (I-CCA therapy) for advanced renal cell carcinoma. Cancer Sci. 2011; 102: 137-43.
16. Rothwell PM, Wilson M, Elwin CE et al. Long-term effect of aspirin on colorectal cancer incidence and mortality: 20-year follow-up of five randomised trials. Lancet 2010; 376: 1741-50.
17. Tillet WS, Francis TJ. Serological reactions in pneumonia with a non-protein somatic fraction of pneumococcus. J. Exp. Med. 1930; 52: 561-571.
18. Bottazzi B, Doni A, Garlanda C, Mantovani A. An integrated view of humoral innate immunity: pentraxins as a paradigm. Annu. Rev. Immunol. 2010; 28: 157-83.
19. Janeway CA Jr, Medzhitov R. Innate immune recognition. Annu. Rev. Immunol. 2002; 20: 197-216.
20. Volanakis JE. Human C-reactive protein: expression, structure, and function. Mol. Immunol. 2001; 38: 189-97.
21. Kushner I, Jiang SL, Zhang D, Lozanski G, Samols D. Do post-transcriptional mechanisms participate in induction of C-reactive protein and serum amyloid A by IL-6 and IL-1? Ann. N. Y. Acad. Sci. 1995; 762: 102-7.
22. Black S, Kushner I, Samols D. C-reactive protein. J. Biol. Chem. 2004; 279: 48487-90.
23. Agrawal A, Samols D, Kushner I. Transcription factor c-Rel enhances C-reactive protein expression by facilitating the binding of C/EBPbeta to the promoter. Mol. Immunol. 2003; 40: 373-80.
24. Jialal I, Devaraj S, Venugopal SK. C-reactive protein: risk marker or mediator in atherothrombosis? Hypertension 2004; 44: 6-11.
25. Kuta AE, Baum LL. C-reactive protein is produced by a small number of normal human peripheral blood lymphocytes. J. Exp. Med. 1986; 164: 321-6.
26. Jabs WJ, Busse M, Kruger S, Jocham D, Steinhoff J, Doehn C. Expression of C-reactive protein by renal cell carcinomas and unaffected surrounding renal tissue. Kidney Int. 2005; 68: 2103-10.
27. Johnson TV, Ali S, Abbasi A et al. Intratumor C-reactive protein as a biomarker of prognosis in localized renal cell carcinoma. J. Urol. 2011; 186: 1213-17.
28. Kushner I. The phenomenon of the acute phase response. Ann. N. Y. Acad. Sci. 1982; 389: 39-48.
29. Vanderschueren S, Deeren D, Knockaert DC, Bobbaers H, Bossuyt X, Peetermans W. Extremely elevated C-reactive protein. Eur. J. Intern. Med. 2006; 17: 430-3.
30. Kushner I, Rzewnicki D, Samols D. What does minor elevation of C-reactive protein signify? Am. J. Med. 2006; 119: 166 e17-28.
31. Rifai N, Ridker PM. High-sensitivity C-reactive protein: a novel and promising marker of coronary heart disease. Clin. Chem. 2001; 47: 403-11.
32. van Leeuwen MA, van der Heijde DM, van Rijswijk MH et al. Interrelationship of outcome measures and process variables in early rheumatoid arthritis. A comparison of radiologic damage, physical disability, joint counts, and acute phase reactants. J. Rheumatol. 1994; 21: 425-9.
33. Nielen MM, van Schaardenburg D, Reesink HW et al. Increased levels of C-reactive protein in serum from blood donors before the onset of rheumatoid arthritis. Arthritis Rheum. 2004; 50: 2423-7.
34. Anderson JL, Carlquist JF, Muhlestein JB, Horne BD, Elmer SP. Evaluation of C-reactive protein, an inflammatory marker, and infectious serology as risk factors for coronary artery disease and myocardial infarction. J. Am. Coll. Cardiol. 1998; 32: 35-41.
35. Danesh J, Wheeler JG, Hirschfield GM et al. C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N. Engl. J. Med. 2004; 350: 1387-97.
36. Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N. Engl. J. Med. 1997; 336: 973-9.
37. Trichopoulos D, Psaltopoulou T, Orfanos P, Trichopoulou A, Boffetta P. Plasma C-reactive protein and risk of cancer: a prospective study from Greece. Cancer Epidemiol. Biomarkers Prev. 2006; 15: 381-4.
38. Proctor MJ, Morrison DS, Talwar D et al. A comparison of inflammation-based prognostic scores in patients with cancer. A Glasgow Inflammation Outcome Study. Eur. J. Cancer 2011; 47: 2633-41.
39. Saito K, Kihara K. Role of C-reactive protein as a biomarker for renal cell carcinoma. Expert Rev. Anticancer Ther. 2010; 10: 1979-89.
40. Masuda H, Kurita Y, Fukuta K, Mugiya S, Suzuki K, Fujita K. Significant prognostic factors for 5-year survival after curative resection of renal cell carcinoma. Int. J. Urol. 1998; 5: 418-22.
41. Lamb GW, McMillan DC, Ramsey S, Aitchison M. The relationship between the preoperative systemic inflammatory response and cancer-specific survival in patients undergoing potentially curative resection for renal clear cell cancer. Br. J. Cancer 2006; 94: 781-4.
42. Komai Y, Saito K, Sakai K, Morimoto S. Increased preoperative serum C-reactive protein level predicts a poor prognosis in patients with localized renal cell carcinoma. BJU Int. 2007; 99: 77-80.
43. Ramsey S, Lamb GW, Aitchison M, McMillan DC. Prospective study of the relationship between the systemic inflammatory response, prognostic scoring systems and relapse-free and cancer-specific survival in patients undergoing potentially curative resection for renal cancer. BJU Int. 2008; 101: 959-63.
44. Johnson TV, Abbasi A, Owen-Smith A et al. Absolute preoperative C-reactive protein predicts metastasis and mortality in the first year following potentially curative nephrectomy for clear cell renal cell carcinoma. J. Urol. 2010; 183: 480-5.
45. Ito K, Asano T, Yoshii H, Satoh A, Sumitomo M, Hayakawa M. Impact of thrombocytosis and C-reactive protein elevation on the prognosis for patients with renal cell carcinoma. Int. J. Urol. 2006; 13: 1365-70.
46. Karakiewicz PI, Hutterer GC, Trinh QD et al. C-reactive protein is an informative predictor of renal cell carcinoma-specific mortality: a European study of 313 patients. Cancer 2007; 110: 1241-7.
47. Iimura Y, Saito K, Fujii Y et al. Development and external validation of a new outcome prediction model for patients with clear cell renal cell carcinoma treated with nephrectomy based on preoperative serum C-reactive protein and TNM classification: the TNM-C score. J. Urol. 2009; 181: 1004-12.
48. Johnson TV, Abbasi A, Owen-Smith A et al. Postoperative Better Than Preoperative C-Reactive Protein at Predicting Outcome After Potentially Curative Nephrectomy for Renal Cell Carcinoma. Urology 2010; 76: 766.e1-5.
49. Ito K, Yoshii H, Sato A et al. Impact of postoperative C-reactive protein level on recurrence and prognosis in patients with N0M0 clear cell renal cell carcinoma. J. Urol. 2011; 186: 430-5.
50. Tatokoro M, Saito K, Iimura Y, Fujii Y, Kawakami S, Kihara K. Prognostic impact of postoperative C-reactive protein level in patients with metastatic renal cell carcinoma undergoing cytoreductive nephrectomy. J. Urol. 2008; 180: 515-19.
51. Bromwich E, McMillan DC, Lamb GW, Vasey PA, Aitchison M. The systemic inflammatory response, performance status and survival in patients undergoing alpha-interferon treatment for advanced renal cancer. Br. J. Cancer 2004; 91: 1236-8.
52. Casamassima A, Picciariello M, Quaranta M et al. C-reactive protein: a biomarker of survival in patients with metastatic renal cell carcinoma treated with subcutaneous interleukin-2 based immunotherapy. J. Urol. 2005; 173: 52-5.
53. Vogl UM, Zehetgruber H, Dominkus M et al. Prognostic factors in metastatic renal cell carcinoma: metastasectomy as independent prognostic variable. Br. J. Cancer 2006; 95: 691-8.
54. Atzpodien J, Royston P, Wandert T, Reitz M. Metastatic renal carcinoma comprehensive prognostic system. Br. J. Cancer 2003; 88: 348-53.
55. Ramsey S, Lamb GW, Aitchison M, Graham J, McMillan DC. Evaluation of an inflammation-based prognostic score in patients with metastatic renal cancer. Cancer 2007; 109: 205-12.
56. Saito K, Tatokoro M, Fujii Y et al. Impact of C-reactive protein kinetics on survival of patients with metastatic renal cell carcinoma. Eur. Urol. 2009; 55: 1145-53.
57. Satomi Y. A clinical study of the prognosis of renal carcinoma - with reference to factors on the part of host. Nippon Hinyokika Gakkai Zasshi 1973; 64: 195-216.
58. Kattan MW. Judging new markers by their ability to improve predictive accuracy. J. Natl. Cancer Inst. 2003; 95: 634-5.
59. Blay JY, Negrier S, Philip T, Favrot M, Mercatello A. Pretreatment serum CRP and response to interleukin 2. Br. J. Cancer 1994; 69: 200-1.
60. Miyake H, Kurahashi T, Takenaka A, Inoue TA, Fujisawa M. Clinical outcome of combined immunotherapy with interferon-alpha and low-dose interleukine-2 for Japanese patients with metastatic renal cell carcinoma. Urol. Oncol. 2009; 27: 598-603.
61. Coppin C, Porzsolt F, Autenrieth M, Kumpf J, Coldman A, Wil T. Immunotherapy for advanced renal cell cancer. Cochrane Database Syst. Rev. 2004; CD001425.
62. Naito S, Yamamoto N, Takayama T et al. Prognosis of Japanese metastatic renal cell carcinoma patients in the cytokine era: a cooperative group report of 1463 patients. Eur. Urol. 2010; 57: 317-25.
63. Motzer RJ, Bacik J, Murphy BA, Russo P, Mazumdar M. Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J. Clin. Oncol. 2002; 20: 289-96.
64. Frank I, Blute ML, Cheville JC, Lohse CM, Weaver AL, Zincke H. An outcome prediction model for patients with clear cell renal cell carcinoma treated with radical nephrectomy based on tumor stage, size, grade and necrosis: the SSIGN score. J. Urol. 2002; 168: 2395-400.
65. Novara G, Martignoni G, Artibani W, Ficarra V. Grading systems in renal cell carcinoma. J. Urol. 2007; 177: 430-6.
66. Cindolo L, Patard JJ, Chiodini P et al. Comparison of predictive accuracy of four prognostic models for nonmetastatic renal cell carcinoma after nephrectomy: a multicenter European study. Cancer 2005; 104: 1362-71.
67. Fukushima H, Tatokoro M, Saito K et al. Diagnostic contribution of C-reactive protein kinetics for gastric metastasis from renal cell carcinoma. Int. Canc. Conf. J. 2012; 1: 93-5.
68. Hilmy M, Bartlett JM, Underwood MA, McMillan DC. The relationship between the systemic inflammatory response and survival in patients with transitional cell carcinoma of the urinary bladder. Br. J. Cancer 2005; 92: 625-7.
69. Saito K, Kawakami S, Ohtsuka Y et al. The impact of preoperative serum C-reactive protein on the prognosis of patients with upper urinary tract urothelial carcinoma treated surgically. BJU Int. 2007; 100: 269-73.
70. Yoshida S, Saito K, Koga F et al. C-reactive protein level predicts prognosis in patients with muscle-invasive bladder cancer treated with chemoradiotherapy. BJU Int. 2008; 101: 978-81.
71. Gakis G, Todenhofer T, Renninger M et al. Development of a new outcome prediction model in carcinoma invading the bladder based on preoperative serum C-reactive protein and standard pathological risk factors: the TNR-C score. BJU Int. 2011; 108: 1800-5.
72. Ishioka J, Saito K, Sakura M et al. Development of a nomogram incorporating serum C-reactive protein level to predict overall survival of patients with advanced urothelial carcinoma and its evaluation by decision curve analysis. Br. J. Cancer (in press).
73. Saito K, Urakami S, Komai Y et al. Impact of C-reactive protein kinetics on survival of patients with advanced urothelial carcinoma treated by second-line chemotherapy with gemcitabine, etoposide, and cisplatin. BJU Int. doi: 10.1111/j.1442-2042.2012.0344.x
74. McArdle PA, Qayyum T, McMillan DC. Systemic inflammatory response and survival in patients with localised prostate cancer: 10-year follow-up. Urol. Int. 2010; 84: 430-5.
75. Nakashima J, Kikuchi E, Miyajima A et al. Simple stratification of survival using bone scan and serum C-reactive protein in prostate cancer patients with metastases. Urol. Int. 2008; 80: 129-33.
76. McArdle PA, Mir K, Almushatat AS, Wallace AM, Underwood MA, McMillan DC. Systemic inflammatory response, prostate-specific antigen and survival in patients with metastatic prostate cancer. Urol. Int. 2006; 77: 127-9.
77. Beer TM, Lalani AS, Lee S et al. C-reactive protein as a prognostic marker for men with androgen-independent prostate cancer: results from the ASCENT trial. Cancer 2008; 112: 2377-83.
78. Prins RC, Rademacher BL, Mongoue-Tchokote S et al. C-reactive protein as an adverse prognostic marker for men with castration-resistant prostate cancer (CRPC): confirmatory results. Urol. Oncol. 2012; 30: 33-7.
79. Ito M, Saito K, Yasuda Y et al. Prognostic impact of C-reactive protein for determining overall survival of patients with castration-resistant prostate cancer treated with docetaxel. Urology 2011; 78: 1131-5.
80. Lehrer S, Diamond EJ, Mamkine B, Droller MJ, Stone NN, Stock RG. C-reactive protein is significantly associated with prostate-specific antigen and metastatic disease in prostate cancer. BJU Int. 2005; 95: 961-2.
81. Van Hemelrijck M, Jungner I, Walldius G et al. Risk of prostate cancer is not associated with levels of C-reactive protein and other commonly used markers of inflammation. Int. J. Cancer 2011; 129: 1485-92.
82. Lee S, Choe JW, Kim HK, Sung J. High-sensitivity C-reactive protein and cancer. J. Epidemiol. 2011; 21: 161-8.
83. Huddart RA, Norman A, Shahidi M et al. Cardiovascular disease as a long-term complication of treatment for testicular cancer. J. Clin. Oncol. 2003; 21: 1513-23.
84. Meinardi MT, Gietema JA, van der Graaf WT et al. Cardiovascular morbidity in long-term survivors of metastatic testicular cancer. J. Clin. Oncol. 2000; 18: 1725-32.
85. Fossa SD, Aass N, Harvei S, Tretli S. Increased mortality rates in young and middle-aged patients with malignant germ cell tumours. Br. J. Cancer 2004; 90: 607-12.
86. Wethal T, Kjekshus J, Roislien J et al. Treatment-related differences in cardiovascular risk factors in long-term survivors of testicular cancer. J. Cancer Surviv. 2007; 1: 8-16.
87. Wethal T, Haugnes HS, Kjekshus J et al. C-reactive protein; a potential marker of second cancer and cardiovascular disease in testicular cancer survivors? Eur. J. Cancer 2010; 46: 3425-33.
88. Orre IJ, Murison R, Dahl AA, Ueland T, Aukrust P, Fossa SD. Levels of circulating interleukin-1 receptor antagonist and C-reactive protein in long-term survivors of testicular cancer with chronic cancer-related fatigue. Brain Behav. Immun. 2009; 23: 868-74.